1. Using CDK4/6 Inhibitors to Manage HR-Positive Metastatic Breast Cancer

3. HR-Positive Breast Cancer

4. Epidemiology of HR-Positive Breast Cancer

5. Common Therapies for HR-Positive Breast Cancer

6. Relapsed and Metastatic Disease

7. NCCN Guidelines for Treatment of Recurrent or Stage IV Disease in Postmenopausal Women

8. MOA for CDK4/6 Inhibitors

9. HR+/HER2- Advanced/MBC

10. Endocrine Therapy Side Effects

11. CDK4/6 Inhibitor Side Effects

12. Cardiotoxicity Monitoring For Patients Treated With Ribociclib

13. CDK4/6 Inhibitor Drug Drug/Food Interactions

14. Neutropenia Associated With CDK4/6 Inhibitors

15. Neutropenia Monitoring

16. Strategies for Optimizing Adherence to Oral Therapies

17. Managing Treatment-Related AEs

18. Summary

19. Abbreviations